Your Health, We Care
Release date: 2024-07-09 17:30:29 Recommended: 162
Sotorasib, also known as Lumakras, is a targeted drug designed for patients with NSCLC carrying the KRAS G12C gene mutation. This medication inhibits the activity of the KRAS G12C protein by directly targeting its specific structural domain, thereby impeding cell growth and proliferation.
Key considerations for the use of Sotorasib include the need for patients to closely monitor their own reactions during treatment and seek medical attention promptly if any discomfort arises.
Sotorasib may induce hepatotoxicity during treatment, as the drug's metabolism in the liver may potentially damage hepatic cells. Patients should undergo regular liver function tests before and during treatment, assessing markers such as liver enzyme levels and bilirubin. If any abnormalities in liver function are detected, patients should promptly communicate with their physician to adjust the treatment plan or discontinue the medication as advised.
ILD and pneumonia are additional potential risks requiring close monitoring during Sotorasib treatment. These conditions may manifest as symptoms such as respiratory distress, coughing, and chest pain. Patients should pay close attention to their respiratory status throughout treatment and seek immediate medical attention if any anomalies arise. Physicians may recommend pulmonary imaging examinations based on the patient's specific circumstances to promptly detect and manage ILD or pneumonia.
Sotorasib is a prescription medication that should be used under medical guidance to avoid self-administration. Patients should carefully read the drug label before use to understand dosage instructions, drug interactions, and potential adverse reactions.
While uncommon, patients may experience the following adverse reactions during Sotorasib use, warranting sufficient attention.
Hemoglobin, a protein in red blood cells responsible for oxygen transport, may decrease due to Sotorasib use, potentially leading to anemia. Patients should undergo regular blood tests to monitor hemoglobin levels.
Aspartate aminotransferase (AST) is a vital indicator of liver function. Sotorasib may result in elevated AST levels, indicating compromised liver function. Patients should undergo regular liver function tests during treatment to monitor AST levels.
Alkaline phosphatase (ALP) is another liver function marker. Sotorasib may elevate ALP, prompting patient vigilance. In case of abnormalities, patients should promptly seek medical attention and inform their physician.
[Warm tips] Patients using Sotorasib should adhere to the aforementioned considerations and monitor for adverse reactions diligently. Adherence to the physician's guidance, regular monitoring, and evaluation are essential. In case of any discomfort or queries, patients should promptly communicate with their physician and seek assistance.
